Identifying nongenetic risk factors for inhibitor development in severe hemophilia A

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 7, 2013, Pages 740-751

  Gouw, Samantha C ^a   Fijnvandraat, Karin ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

antibody; etiology; FVIII; prophylaxis; tolerance; treatment

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; PLASMA DERIVED BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; BREAST FEEDING; BREAST MILK; CATHETER INFECTION; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG EXTRAVASATION; DRUG MEGADOSE; GENE MUTATION; HEMOPHILIA A; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMPLANTATION; INTENSIVE CARE; JOINT INJURY; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORBIDITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW (TOPIC); VACCINATION;

COHORT STUDIES; FACTOR VIII; HEMOPHILIA A; HUMANS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84885081117     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1354417     Document Type: Article

References (65)

1. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion: 1999; 39 11-12 1160 1168
2. Wight J., Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia: 2003; 9 4 418 435 (Pubitemid 36874391)
3. Gringeri A., Mantovani L. G., Scalone L., Mannucci P. M.; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood: 2003; 102 7 2358 2363 (Pubitemid 37193570)
4. Leissinger C., Cooper D. L., Solem C. T.; HTRS Investigators. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. Haemophilia: 2011; 17 6 884 889
5. Morfini M., Haya S., Tagariello G., et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia: 2007; 13 5 606 612 (Pubitemid 47338004)
6. Hay C. R., DiMichele D. M.; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood: 2012; 119 6 1335 1344
7. Wight J., Paisley S., Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia: 2003; 9 4 436 463 (Pubitemid 36874392)
8. Astermark J., Oldenburg J., Pavlova A., Berntorp E., Lefvert A. K.; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood: 2006; 107 8 3167 3172
9. Astermark J., Oldenburg J., Carlson J., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood: 2006; 108 12 3739 3745 (Pubitemid 44864553)
10. Astermark J., Donfield S. M., Gomperts E. D., et al. Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood: 2013; 121 8 1446 1454
11. Gouw S. C., van den Berg H. M., Oldenburg J., et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood: 2012; 119 12 2922 2934
12. Hay C. R., Ollier W., Pepper L., et al. UKHCDO Inhibitor Working Party. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost: 1997; 77 2 234 237 (Pubitemid 27084906)
13. Oldenburg J., Picard J. K., Schwaab R., Brackmann H. H., Tuddenham E. G., Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost: 1997; 77 2 238 242 (Pubitemid 27084907)
14. Schwaab R., Brackmann H. H., Meyer C., et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost: 1995; 74 6 1402 1406 (Pubitemid 26018063)
15. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol: 1994; 12 991 1045 (Pubitemid 24140436)
16. Reipert B. M., van Helden P. M., Schwarz H. P., Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol: 2007; 136 1 12 25 (Pubitemid 44912584)
17. Gouw S. C., van der Bom J. G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood: 2007; 109 11 4648 4654 (Pubitemid 46827754)
18. Gouw S. C., van den Berg H. M., le Cessie S., van der Bom J. G. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost: 2007; 5 7 1383 1390 (Pubitemid 46965364)
19. Maclean P. S., Richards M., Williams M., et al. Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia: 2011; 17 2 282 287
20. Gouw S. C., van den Berg H. M., Fischer K., et al. PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood: 2013; 121 20 4046 4055
21. Eckhardt C. L., van der Bom J. G., van der Naald M., Peters M., Kamphuisen P. W., Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost: 2011; 9 10 1948 1958
22. Rivard G. E., Lillicrap D., Poon M. C., et al. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age? Haemophilia: 2005; 11 4 335 339 (Pubitemid 41030832)
23. Santagostino E., Mancuso M. E., Rocino A., et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol: 2005; 130 3 422 427 (Pubitemid 43899592)
24. Kenet G., Lubetsky A., Luboshitz J., et al. Early single exposure to factor concentrates does not increase the risk for inhibitor development. Haemophilia: 2006; 12 02 63 (abstract 14 PO 395)
25. Elalfy M. S., Elbarbary N. S., Eldebeiky M. S., El Danasoury A. S. Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children. Pediatr Hematol Oncol: 2012; 29 5 485 493
26. Kurnik K., Bidlingmaier C., Engl W., Chehadeh H., Reipert B., Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia: 2010; 16 2 256 262
27. Auerswald G., Bidlingmaier C., Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients-long-term follow-up and continuing experience. Haemophilia: 2012; 18 1 e18 e20
28. Morado M., Villar A., Jiménez Yuste V., Quintana M., Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia: 2005; 11 2 79 83 (Pubitemid 40468053)
29. Shirahata A., Fukutake K., Higasa S., et al. STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan. Haemophilia: 2011; 17 5 771 776
30. Suzuki T., Arai M., Amano K., Kagawa K., Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost: 1996; 76 5 749 754 (Pubitemid 26388181)
31. Wadhwa M., Dilger P., Tubbs J., Mire-Sluis A., Barrowcliffe T., Thorpe R. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood: 1994; 84 6 2021 2030 (Pubitemid 24286155)
32. Raut S., Weller L., Barrowcliffe T. W. Phospholipid binding of factor VIII in different therapeutic concentrates. Br J Haematol: 1999; 107 2 323 329 (Pubitemid 29530218)
33. Franchini M., Tagliaferri A., Mengoli C., Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol: 2012; 81 1 82 93
34. Iorio A., Halimeh S., Holzhauer S., et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost: 2010; 8 6 1256 1265
35. Mannucci P. M., Gringeri A., Peyvandi F., Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia: 2007; 13 05 65 68 (Pubitemid 350253407)
36. Peerlinck K., Arnout J., Gilles J. G., Saint-Remy J. M., Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost: 1993; 69 2 115 118 (Pubitemid 23041179)
37. Rosendaal F. R., Nieuwenhuis H. K., van den Berg H. M., et al. Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood: 1993; 81 8 2180 2186 (Pubitemid 23106736)
38. Gouw S. C., van der Bom J. G., Auerswald G., Ettinghausen C. E., Tedgård U., van den Berg H. M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood: 2007; 109 11 4693 4697 (Pubitemid 46827760)
39. Aledort L. M., Navickis R. J., Wilkes M. M. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost: 2011; 9 11 2180 2192
40. Iorio A., Marcucci M., Makris M. Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost: 2011; 9 11 2176 2179
41. Gouw S. C., van der Bom J. G., Ljung R., et al. PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med: 2013; 368 3 231 239
42. Giangrande P. L.; KOGENATE Bayer Study Group. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia: 2002; 8 02 19 22 (Pubitemid 34498624)
43. Kreuz W., Gill J. C., Rothschild C., et al. International Kogenate-FS Study Group. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost: 2005; 93 3 457 467 (Pubitemid 40392533)
44. Pahl S., Pavlova A., Driesen J., Müller J., Pötzsch B., Oldenburg J. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile. Haemophilia: 2013; 19 3 392 398
45. Baglin T., Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Thromb Haemost: 1998; 80 6 1036 1037 (Pubitemid 28556718)
46. Bacon C. L., Singleton E., Brady B., et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia: 2011; 17 3 407 411
47. Kocher S., Asmelash G., Makki V., et al. [Inhibitor development after changing FVIII/IX products in patients with haemophilia]. Hamostaseologie: 2012; 32 01 S39 S42
48. Janeway ChA Jr, Travers P., Walport M. Principles of innate and adaptive immunity. In: Immunobiology: The Immune System in Health and Disease. 5th ed. New York Garland Science: 1997; 1:1-1:30
49. Peng A., Gaitonde P., Kosloski M. P., Miclea R. D., Varma P., Balu-Iyer S. V. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci: 2009; 98 12 4480 4484
50. Oldenburg J., Schwaab R., Brackmann H. H. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang: 1999; 77 01 49 54 (Pubitemid 29469258)
51. Strauss T., Lubetsky A., Ravid B., et al. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia: 2011; 17 4 625 629
52. Yee T. T., Lee C. A. Oral immune tolerance induction to factor VIII via breast milk, a possibility? Haemophilia: 2000; 6 5 591
53. Jansen I. M., Fischer K., Van Der Bom J. G., Van Den Berg H. M. No protective effect of breastfeeding on inhibitor formation in severe hemophilia. Pediatr Hematol Oncol: 2005; 22 7 575 580 (Pubitemid 41362234)
54. Knobe K. E., Tengborn L. I., Petrini P., Ljung R. C. Breastfeeding does not influence the development of inhibitors in haemophilia. Haemophilia: 2002; 8 5 657 659
55. von Auer Ch, Oldenburg J., von Depka M., et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci: 2005; 1051 498 505 (Pubitemid 41363770)
56. Auerswald G., Bade A., Haubold K., Overberg D., Masurat S., Moorthi C. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study. Haemophilia: 2013; 19 3 438 444
57. Batorova A., Holme P., Gringeri A., et al. European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. Haemophilia: 2012; 18 5 753 759
58. Batorova A., Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol: 2006; 13 5 308 315 (Pubitemid 44168450)
59. Dhadwar S. S., Kiernan J., Wen J., Hortelano G. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. J Thromb Haemost: 2010; 8 12 2743 2750
60. Kitazawa T., Igawa T., Sampei Z., et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med: 2012; 18 10 1570 1574
61. Welch E. M., Barton E. R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature: 2007; 447 7140 87 91 (Pubitemid 46685839)
62. Nathwani A. C., Tuddenham E. G., Rangarajan S., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med: 2011; 365 25 2357 2365
63. High K. A. The gene therapy journey for hemophilia: are we there yet? Blood: 2012; 120 23 4482 4487
64. Wang J., Lozier J., Johnson G., et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol: 2008; 26 8 901 908
65. Barbosa M. D., Celis E. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today: 2007; 12 15-16 674 681 (Pubitemid 47238643)